CDK4 and breast neoplasm: While CDK4/6 inhibitors like Palbociclib in combination with TAM may potentially arrest the in vivo growth of ERmut expressing breast tumors, CDK2 inhibitors like Dinaciclib when given in combination with TAM may be more effective by inducing regressions in established ERmut expressing tumors.